Invesco
LCTX icon

Invesco’s Lineage Cell Therapeutics LCTX Stock Holding History

Invesco’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$131K Buy
+100,129
New +$138K ﹤0.01% 3700
2025
Q2 		– Sell
-58,038
Closed -$26.2K – 3816
2025
Q1 		$26.2K Sell
58,038
-3,747
-6% -$2.2K ﹤0.01% 3734
2024
Q4 		$31K Buy
61,785
+1,272
+2% +$934 ﹤0.01% 3726
2024
Q3 		$54.8K Buy
60,513
+3,749
+7% +$3.48K ﹤0.01% 3674
2024
Q2 		$56.6K Buy
56,764
+15
+0% +$17 ﹤0.01% 3811
2024
Q1 		$84K Sell
56,749
-130
-0.2% -$147 ﹤0.01% 3761
2023
Q4 		$62K Sell
56,879
-9,013
-14% -$9.87K ﹤0.01% 3735
2023
Q3 		$77.8K Hold
65,892
– – ﹤0.01% 3756
2023
Q2 		$92.9K Buy
+65,892
New +$91.1K ﹤0.01% 3741
2022
Q2 		– Sell
-34,518
Closed -$53K – 4094
2022
Q1 		$53K Sell
34,518
-7,765
-18% -$12K ﹤0.01% 3927
2021
Q4 		$103K Sell
42,283
-13,360
-24% -$31.3K ﹤0.01% 3898
2021
Q3 		$140K Buy
55,643
+11,196
+25% +$28.7K ﹤0.01% 3879
2021
Q2 		$126K Buy
+44,447
New +$115K ﹤0.01% 3862
2019
Q1 		– Sell
-33,796
Closed -$31K – 3764
2018
Q4 		$31K Sell
33,796
-4,491
-12% -$6.88K ﹤0.01% 3735
2018
Q3 		$79K Sell
38,287
-6,268
-14% -$13.2K ﹤0.01% 3799
2018
Q2 		$80K Sell
44,555
-77,279
-63% -$156K ﹤0.01% 3787
2018
Q1 		$287K Sell
121,834
-4,830
-4% -$11.3K ﹤0.01% 3512
2017
Q4 		$238K Sell
126,664
-1,894
-1% -$4.14K ﹤0.01% 3502
2017
Q3 		$319K Sell
128,558
-767
-0.6% -$1.9K ﹤0.01% 3436
2017
Q2 		$356K Buy
+129,325
New +$361K ﹤0.01% 3430
2015
Q3 		– Sell
-1,643
Closed -$5K – 3898
2015
Q2 		$5K Buy
+1,643
New +$6.37K ﹤0.01% 4204

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Invesco's LCTX Position: Q2 2026 in Review

Invesco opened a new position in Lineage Cell Therapeutics (LCTX) in Q2 2026: 100,129 shares worth $131K. The stake represents ﹤0.01% of the portfolio and ranks #3700 among its holdings. This is a return to the name: Invesco previously reported a position in LCTX as recently as Q1 2025.

Invesco first reported a position in LCTX in Q2 2015 and has held it in 21 quarters since. The position peaked at $356K in Q2 2017. 132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

  • Invesco held 100,129 shares of Lineage Cell Therapeutics worth $131K as of Q2 2026.
  • Lineage Cell Therapeutics was a new Invesco position in Q2 2026.
  • Lineage Cell Therapeutics made up ﹤0.01% of Invesco's portfolio in Q2 2026, its #3700 holding.
  • Invesco first reported a position in Lineage Cell Therapeutics in Q2 2015 and has held it in 21 quarters since.
  • Invesco's Lineage Cell Therapeutics position peaked at $356K in Q2 2017.
  • 132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.